System Maintenance Notice

Please note that maintenance work is scheduled between 4 AM and 5 AM - CET. During this time, you may experience reduced performance. Thanks for your patience.

Thomas Berg is an expert in Hepatology at University Hospital Leipzig (Germany). As of October 2026, ScienceLeadR ranks Thomas Berg in the top 1% of experts worldwide for Hepatitis, Liver Cirrhosis and Liver Failure. Thomas Berg has authored 960 publications, the most recent in 2026, and is an investigator in 55 clinical trials, 13 of them ongoing. SLR score: 3,649 (community average: 125). How the SLR is computed.

LeadR Profile

Thomas Berg University Hospital Leipzig Germany
3 649 ScienceLeadR Reputation 3649

Unlock

Register Login
Network Map

Hepatology

Subspecialties: Gastroenterology - Infectiology

Full career – Last 3 years

Main Topics

Publications and Clinical Studies

Publications – Clinical Studies

Profile data updated on

Expert Rankings

Top experts on the MeSH terms this expert works on

Organizations

Career arc: 1994 - 2026
Source: PubMed

Leipzig University

Publications Synthesis

Sources: PubMed, OpenAlex

Number : 960

Citations

Citations: 62 183 1st author: 62 Last author: 146 Unique author: 12

Main journals

J Hepatol 208
Hepatology 60
Z Gastroenterol 58
Gastroenterology 41
PLoS One 24

Best Journals

J Hepatol 40
N Engl J Med 10
Ann Oncol 2

Breakdown by type

Click a legend label to hide or show it in the chart.

Latest Publications

5 most recent indexed articles

Source: Pubmed

Title Journal Year Citations
Prognostic Value of Liver Function and Tumor Burden Scores in Patients with HCC After Transarterial Radioembolization - Retrospective Single Center Analysis.
PMID 42593561 — neoplasms, liver, gastrointestinal neoplasms, tumor burden, therapeutics		J Gastrointest Cancer20260
Corrigendum to "Development and validation of the A-TANGO organ failure score for acute-on-chronic liver failure in global cohorts" [J Hepatol 85 (2026) 91-105].
PMID 42502052 — liver diseases, acute-on-chronic liver failure, liver, liver failure		J Hepatol Top journal20260
[S2k guideline Gastrointestinal Bleeding of the German Society of Gastroenterology, Digestive and Metabolic Diseases (DGVS) - December 2025 - Version 2.0 - AWMF registration number: 021-028].
PMID 42486077 — hemorrhage, gastroenterology, metabolic diseases		Z Gastroenterol20261
Corrigendum to: "HBsAg protein composition and clinical outcomes in chronic hepatitis D and variations across HBeAg-negative chronic HBsAg carriers" [JHEP Reports 5 (2023) 100842].
PMID 42418959 — hepatitis b surface antigens, hepatitis d, hepatitis d, chronic, hepatitis, chronic, hepatitis b e antigens, hepatitis		JHEP Rep20260
When Biology Pushes Back: Lessons From HBsAg-Targeting Therapies in Hepatitis Delta.
PMID 42401242 — liver diseases, hepatitis b surface antigens, hepatitis d, liver, therapeutics, hepatitis		J Hepatol Top journal20260

Clinical Studies 55

Sources: ClinicalTrials, EU CTIS

Synthesis

Principal Investigator: 4 Study Chair: 2 Study Director: 1

By phase:

Phase 3 20
N/A 16
Phase 2 11
Phase 4 6
Phase 1 1
Phase 3/Phase 4 1

By status:

Completed 33
Recruiting 12
Active not recruiting 4
Unknown 4
No longer available 1
Terminated 1

By type:

Interventional 45
Observational 9
Expanded Access 1

By Monocentric/Multicentric:

monocentric 12
multicentric2to4 2
multicentric5to9 1
multicentricup10 40

Main Topics

Cohort/Consortium Investigators 4

Ongoing Clinical Trials

13 ongoing trials started since 2021, where this expert is an investigator

Source: ClinicalTrials

Study Phase Status Start
A study to investigate the safety and efficacy of GSK4532990 compared with placebo in adult participants aged 18 to 70 years with alcohol related liver disease
2024-511596-15-00 — liver diseases, safety, liver, aged		Phase 2Recruiting2024
A Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction Associated Steatotic Liver Disease (SYNERGY Outcomes)
2025-522674-36-00 — liver diseases, liver		Phase 3Recruiting2026
An Open label study of patients with primary sclerosing cholangitis (PSC) treated with norucholic acid tablets
2024-514292-18-00 — cholangitis, tablets, cholangitis, sclerosing		Phase 3Active not recruiting2025
A Phase 3 Randomized Double Blind Placebo Controlled Study Evaluating the Safety and Efficacy of Efruxifermin in Subjects with Non Cirrhotic Nonalcoholic Steatohepatitis (NASH) Metabolic Dysfunction Associated Steatohepatitis (MASH) and Fibrosis
2023-505141-48-00 — safety, fibrosis, non-alcoholic fatty liver disease, alcoholics		Phase 3Recruiting2024
A Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction Associated Steatotic Liver Disease (SYNERGY Outcomes)
NCT07165028 — liver diseases, non-alcoholic fatty liver disease, liver, alcoholics, incretins, fatty liver, fatty liver, alcoholic		Phase 3Recruiting2025

LeadR Networks

Main global connection map

Sources: PubMed, OpenAlex, ClinicalTrials, EU CTIS